hVIVO CEO discusses Human Challenge Trials and relocation to Canary Wharf

hVIVO’s CEO addressed the Canary Wharf group, discussing their world-leading title in human challenge trials and the company’s relocation to Canary Wharf. Yamin ‘Mo’ Khan emphasised hVIVO’s fit-for-purpose facility, featuring a 50-bed quarantine unit, and highlighted the benefits of joining the life science community at Canary Wharf.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this